Profiling of FSHR Negative Allosteric Modulators on LH/CGR Reveals
  Biased Antagonism with Implications in Steroidogenesis by Ayoub, Mohammed Akli et al.
Profiling of FSHR Negative Allosteric Modulators on LH/CGR Reveals
Biased Antagonism with Implications in Steroidogenesis
Mohammed Akli Ayoub1,2,*, Romain Yvinec1, Gwenhaël Jégot1, James A. Dias3, 
Sonia-Maria Poli4, Anne Poupon1, Pascale Crépieux1, and Eric Reiter1
1 PRC, INRA, CNRS, IFCE, Université de Tours, 37380, Nouzilly, France.
2 LE STUDIUM® Loire Valley Institute for Advanced Studies, 45000, Orléans, France. 
3 Department of Biomedical Sciences, State University of New York at Albany, Albany, New York. 
4 Addex Pharma S.A, Plan-les-Ouates, Geneva, Switzerland.
*  Correspondence:  Institut  National  de  la  Recherche  Agronomique  (INRA)  UMR85,  CNRS-
Université François-Rabelais UMR7247, Physiologie de la Reproduction et des Comportements - 
Nouzilly 37380, France - Email: Mohammed.Ayoub@tours.inra.fr 
Abstract 
Biased signaling has recently emerged as an interesting means to modulate the function of many G 
protein-coupled receptors (GPCRs). Previous studies reported two negative allosteric modulators 
(NAMs)  of  follicle-stimulating  hormone  receptor  (FSHR),  ADX68692  and  ADX68693,  with 
differential effects on FSHR-mediated steroidogenesis and ovulation. In this study, we attempted to 
pharmacologically  profile  these  NAMs  on  the  closely  related  luteinizing  hormone/chorionic 
gonadotropin hormone receptor (LH/CGR) with regards to its canonical Gs/cAMP pathway as well 
as  to  ß-arrestin  recruitment  in  HEK293  cells.  The  NAMs’  effects  on  cAMP,  progesterone  and 
testosterone production were also assessed in murine Leydig tumor cell line (mLTC-1) as well as 
primary rat Leydig cells. We found that both NAMs strongly antagonized LH/CGR signaling in the 
different cell models used with ADX68693 more potent than ADX68692 to inhibit hCG-induced 
cAMP production in HEK293, mLTC-1 and Leydig cells  as well  as ß-arrestin  2 recruitment  in 
HEK293  cells.  Interestingly,  differential  antagonism  of  the  two  NAMs  on  hCG-promoted 
steroidogenesis in mLTC-1 and Leydig cells was observed, eventhough both NAMs inhibited cAMP 
pathways. Indeed, while a significant inhibition of testosterone production by the two NAMs was 
observed in both cell types, progesterone production was only inhibited by ADX68693 in primary 
rat Leydig cells. In addition, while ADX68693 totally abolished testosterone production at 10 µM, 
ADX68692  had  only  a  partial  effect  in  both  mLTC-1  and  primary  rat  Leydig  cells.  These 
observations suggest biased effects of the two NAMs on LH/CGR-dependent pathways controlling 
steroidogenesis.  Interestingly,  the  pharmacological  profiles  of  the  two  NAMs  with  respect  to 
steroidogenesis  were  found to  differ  from that  previously  shown on FSHR.  This  illustrates  the 
complexity  of  signaling  pathways  controlling  FSHR-  and  LH/CGR-mediated  steroidogenesis, 
suggesting  differential  implication  of  cAMP and  ß-arrestins  mediated  by  FSHR and  LH/CGR. 
Together, our data demonstrate that ADX68692 and ADX68693 are biased NAMs at the LH/CGR in 
addition to the FSHR. These pharmacological characteristics are important to consider for potential 
contraceptive and therapeutic applications based on such compounds. 
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1. Introduction 
The  follicle-stimulating  hormone  receptor  (FSHR)  and  luteinizing  hormone/chorionic 
gonadotropin  hormone  receptor  (LH/CGR)  are  G  protein-coupled  receptor  (GPCR)  members 
known for their central role in the control of reproduction. Thus, a particular interest has been given 
to these two receptors with regards to infertility,  contraception,  estrogen-dependent diseases and 
other disorders of the reproductive system in medicine  and in animal husbandry. One of the most 
important aspects in the recent advances on FSHR and LH/CGR is related to the development of 
small molecules to positively or negatively modulate their activity with the aim to better understand 
their  mechanism  of  activation  and  to  develop  potential  therapeutics.  These  agents  may  act  as 
orthosteric ligands at the binding site or as allosteric modulators. Indeed, many studies reported 
small  molecules  as  potential  tools  to  study  underlying  mechanisms  that  enable  successful 
reproduction . In addition, small molecules acting on FSHR and LH/CGR have been proposed as 
alternative  oral  therapeutics  for  infertility  treatment  (agonists)  or  contraception  strategies 
(antagonists) . Small molecule agonists of LH/CGR were reported to efficiently induce ovulation . 
Moreover, dimeric molecules were developed with dual effects as antagonist on FSHR  and agonist 
on  LH/CGR .  For  FSHR,  recent  studies  reported  interesting  small  molecules  acting  either  as 
antagonists , negative allosteric modulators (NAMs)  or as positive allosteric modulators (PAMs) or 
agonists . Indeed, a thiazolidinone derivative has been reported to activate FSHR signaling in CHO 
cells  and  estradiol  production  in  cultured  rat  granulosa  cells  .  Optimization  of  substituted 
benzamides led to more FSHR-selective molecules relative to other closely related GPCRs, such as 
LH/CGR  and  thyroid  stimulating  hormone  receptor  (TSHR)  with  better  pharmacokinetic 
properties . 
The initial FSHR NAM molecule reported was ADX61623, which blocked FSHR-mediated 
cAMP as well as progesterone but not estradiol production in rat granulosa primary cells . However,  
ADX61623 did not affect FSH-induced preovulatory follicle development, limiting its application as 
a  nonsteroidal  contraceptive  .  Two  other  NAMs,  ADX68692  and  ADX68693,  with  structural 
similarities to ADX61623, were tested and exhibited different antagonistic profile on FSHR in rat 
granulosa primary cells . In fact, while ADX68692 blocked FSHR-promoted cAMP, progesterone 
and estradiol production, ADX68693 inhibited cAMP and progesterone with the same efficacy as 
ADX68692 but did not block estradiol production . This study proposed a potential application of 
ADX68692 as a nonsteroidal contraceptive since it was also orally active in blocking FSH-induced 
follicular  growth. Based on the functional difference between both analogs,  it  appeared that the 
contraceptive effects require the blockade of the production of both progesterone and estradiol. Both 
FSHR and  LH/CGR are  involved  in  the  control  of  steroid  sex  hormones,  are  co-expressed  in 
granulosa cells at specific stages , belong to leucine-rich repeat sub-family of GPCRs and are known 
to couple to the canonical Gs/cAMP/PKA signaling pathway . Because of the important structural 
similarity  between  FSHR and  LH/CGR at  the  level  of  their  transmembrane  domains,  one  can 
hypothesize  that  ADX68692  and  ADX68693  may  also  modulate  LH/CGR  activity  thereby 
expanding the spectra of their pharmacological actions. Moreover, previous studies revealed biased 
inhibitory profiles of ADX68692 versus ADX68693 on FSHR-mediated steroidogenesis, albeit the 
molecular mechanisms underneath remained unknown. Noteworthy, FSHR and LH/CGR have been 
reported to be susceptible to biased activation  with implication of the non-canonical ß-arrestin-
dependent signaling pathway . In this context, it is still unclear whether the two ADX compounds 
may have biased antagonistic effects involving preferential actions on G proteins versus ß-arrestins. 
In  this  study,  we  pharmacologically  profiled  the  two  compounds,  ADX68692  and 
ADX68693, on LH/CGR. For this, we investigated their effects on the canonical Gs/cAMP pathway 
as  well  as  on  ß-arrestin  2  recruitment  in  HEK293 cells  using  BRET technology  as  previously 
described . Moreover, the action of these NAMs was examined in mLTC-1 as well as primary rat 
Leydig cells known to endogenously express LHR , by assessing their effects on hCG-promoted 
cAMP, progesterone and testosterone production. Finally, to further explore the differential effects of 
the two NAMs with respect to the different hCG-promoted responses in mLTC-1 and primary rat 
Leydig cells bias factors were calculated.
2. Materials and Methods 
2.1. Materials and plasmids
The FSHR NAMs ADX68692 (MW 401.44) and ADX68693 (MW 352.42) were prepared 
by Addex Pharmaceuticals S.A (Geneva, Switzerland). The specificity of each of the FSHR NAMs 
was  reported  previously  .  The  plasmid  encoding  human  FSHR  was  generated  as  previously 
described   and  hLHR  plasmid  was  obtained  from  A.  Ulloa-Aguirre  (Universidad  Nacional 
Autónoma de México, México, Mexico). The other plasmids encoding the different BRET/FRET 
sensors and fusion proteins were generously provided as follows: Rluc8-fused hLH/CGR from A. 
Hanyaloglu (Imperial College, London, UK), yPET-ß-arrestin 2 from M.G. Scott (Cochin Institute, 
Paris, France), CAMYEL from L.I. Jiang (University of Texas, Texas, USA), V2R-Rluc8 from K.D. 
Pfleger (Harry Perkins Institute  of Medical  Research,  Perth,  Australia).  Recombinant  hFSH was 
kindly gifted by Merck-Serono (Darmstadt, Germany), hCG was kindly donated by Y. Combarnous 
(CNRS,  Nouzilly,  France),  and  desmopressin  (DDAVP)  a  synthetic  form  of  vasopressin  was 
purchased from Sigma-Aldrich (St. Louis, MO, USA). Ninety-six-and 384-well white microplates 
were from Greiner Bio-One (Courtaboeuf, France). Coelenterazine h substrate was purchased from 
Interchim (Montluçon, France). 
2.2. Cell culture and transfection 
HEK293 cells were grown in complete medium (DMEM supplemented with 10% (v/v) fetal 
bovine serum, 4.5 g/l glucose, 100 U/ml penicillin, 0.1 mg/ml streptomycin, and 1 mM glutamine, 
all from Invitrogen, Carlsbad, CA). Transient transfections were performed in 96-well plates using 
Metafectene PRO (Biontex, München, Germany) following the manufacturer’s protocol. Briefly, for 
each well  the different  combinations  of  coding plasmids  were used as  follows:  200 ng of total 
plasmid per well were resuspended in 25 µl of serum-free DMEM and mixed with Metafectene PRO 
(0.5 µl/well) previously preincubated 5 minutes at room temperature in 25 µl serum-free DMEM 
(2x25 µl/well). Then the two solutions of serum-free DMEM containing plasmids and Metafectene 
PRO were mixed and incubated for 20 minutes at room temperature. Cells (105 in 200 µl/well) were 
then incubated with the final plasmid-Metafectene PRO mix (50 µl/well) and cultured in DMEM 
supplemented with 10% fetal bovine serum for forty-eight hours before experiments. 
2.2. Leydig cells isolation
Leydig cells were isolated from the testes of mature 52-day-old Wistar rats as previously 
described (Matinat et al, 2005).
2.3. BRET measurements 
Forty-eight hours after transfection, cells were washed with PBS and BRET measurements 
were performed depending on the experiments, as described previously . For the endpoint dose-
response analyses, cells were first preincubated for 20 minutes at 37°C in the presence or absence of 
increasing concentrations of ADX68692 and ADX68693 in 30 µl/well of PBS 1X, HEPES 5 mM. 
Then, 10 µl/well of increasing doses of 4X hCG in PBS 1X, HEPES 5 mM were added and cells 
were incubated for 30 minutes at 37°C as indicated. Then BRET measurements were performed 
upon addition of 10 µl/well of 5X (5 µM final concentration) coelenterazine h in PBS 1X, HEPES 5 
mM  using  a  Mithras  LB  943  plate  reader.  For  the  real-time  BRET  kinetics,  cells  were  first 
resuspended in 30 µl/well of PBS 1X, HEPES 10 mM containing or not 10 µM of ADX68692 and 
ADX68693 and then BRET measurements were immediately performed upon addition of 10 µl/well 
of coelenterazine h (5 µM final concentration) and 10 µl/well of hCG (5-fold concentrated). 
2.4. cAMP accumulation measured by Glosensor™ assay 
For the measurement of cAMP accumulation, we also used the Glosensor™ cAMP assay 
(Promega).  Growing  cells  in  96-well  plates  (80,000  cells  per  well)  in  growing  medium  were 
incubated overnight at 37°C. On the following day, culture medium was removed and replaced by 
100 μl of equilibration medium per well (DMEM-serum free medium with 4% v/v of GloSensor™ 
cAMP reagent stock solution) and cells were incubated for 2 hours at room temperature. Then, cells 
were incubated for 20 minutes in the presence or absence of increasing concentrations of FSHR 
NAMs before  stimulation  with  FSH (1.3  nM) and rapid  measurement  of  luciferase  signal  was 
peformed using a POLARstar OPTIMA luminometer (BMG Labtech, Ortenberg, Germany).
2.5. cAMP accumulation measured by HTRF® 
Intracellular cAMP levels were measured using a homogeneous time-resolved fluorescence 
(HTRF®)  cAMP  dynamic  assay  kit  (CisBio  Bioassays,  Bagnol  sur  Cèze,  France).  Cells  were 
detached and first resuspended in PBS 1X, 10 mM HEPES, 0.1% BSA containing or 10 µM of 
ADX68692 or ADX68693. After incubation for 20 minutes at 37°C, 5 µl/well (~5000 cells) of cells 
were seeded into white 384-well microplate and supplemented with 5 µl/well  of the stimulation 
buffer in the absence or presence of hCG as indicated. Cells were then incubated for 30 minutes at  
37°C before lysis by addition of 10 µl/well of the supplied conjugate lysis buffer containing d2-
labeled cAMP and Europium cryptate-labeled anti-cAMP antibody, both reconstituted according to 
the manufacturer’s instructions. The plate was incubated for 1 h in the dark at room temperature and 
fluorescence was measured at 620 nm and 665 nm respectively, 50 ms after excitation at 320 nm 
using a Mithras LB 943 plate reader (Berthold Technologies GmbH & Co. Wildbad, Germany).
2.6. cAMP reporter gene assay 
HEK293 cells were transiently co-transfected with plasmids encoding the FSHR or LH/CGR 
and pSOM-Luc coding for a cAMP-sensitive reporter gene, as previously reported . After overnight 
starvation in DMEM-serum free, cells were first pretreated or not for 1 hour at 37°C with 10 µM of 
ADX68692 and ADX68693 in DMEM-serum free. Then, cells were stimulated for 6 hours at 37°C 
with increasing concentrations of gonadotropins in a final volume of 50 µl/well DMEM-serum free. 
Luciferase  luminescence was measured on a Mithras  LB 943 plate  reader  upon addition  of 50 
µl/well of Bright-Glo™ luciferase substrate in the supplied lysis buffer and incubation of cells for 2-
5 minutes at room temperature. 
2.7. Progesterone and testosterone production 
The production of progesterone and testosterone in mLTC-1 and freshly isolated rat Leydig 
cells was assessed using a homogenous time–resolved fluorescence (HTRF®)-based assay (CisBio 
Bioassays, Codolet, France). mLTC-1 cells were first cultured in 96-well microplates and starved 
overnight  in  serum-free  RPMI-1640  medium  containing  25  mM  HEPES  and  0.3  g/L  of  L-
glutamine. The primary rat Leydig cells were resuspenend and seeded in 96-well plate to ~50000 
cells/well in 50 µL/well. Cells were pre-treated for 1 hour at 37°C with 10 µM of ADX68692 or 
ADX68693 prepared in 50 µL/well in serum-free RPMI-1640 medium containing 25 mM HEPES 
and 0.3 g/L of L-glutamine, then stimulated with increasing concentrations of hCG by adding 10 
µL/well of hCG prepared 6X in serum-free RPMI-1640 medium containing 25 mM HEPES and 0.3 
g/L of L-glutamine. After incubation 24 hours for mLTC-1 cells and 3 hours for freshly isolated rat 
Leydig  cells  at  37°C,  10  µL  of  the  culture  supernatant  were  transferred  to  a  white  384-well 
microplate and mixed with 10 µL/well of either progesterone or testosterone. HTRF® reagents (5 µL 
of Europium cryptate-conjugated anti-progesterone/testosterone antibody + 5 µL of d2-conjugated 
progesterone/testosterone) previously resupended in the supplied conjugate lysis buffer. The 384-
well microplate was then incubated for 1 hour at room temperature in the dark before fluorescence 
was measured at 620 nm and 665 nm respectively, 50 ms after excitation at 320 nm using a Mithras 
LB 943 plate reader (Berthold Technologies GmbH & Co. Wildbad, Germany). 
2.8. Data and statistical analysis 
Data are presented as “% of response” by taking as 100% the maximal responses of the 
hormone at 100 nM measured in cells treated with hCG + DMSO in the different assays (dotted 
lines in the dose curves). The kinetic curves and the sigmoidal dose-responses curves were fitted 
using Prism 5 graphing software (GraphPad, La Jolla, CA, USA). Two-way ANOVA analysis using 
Turkey’s  multiple  comparisons  test  was  used  to  determine  statistically  significant  differences 
between the different conditions. *** p-value < 0.001, ** p-value < 0.01, * p-value < 0.05.
2.9. Bias calculations 
Transduction coefficients (R= τ /Ka) and bias factor (B.F.) were obtained after statistical 
fitting of the operational model  for each dose-response curve. Specifically, we followed a similar 
procedure as in [van der Westhuizen,  2014]. For a given hCG-induced response, in the absence 
(DMSO) or presence of ADX68692 or ADX68693, the dose-response curves were fitted using the 
operational model given by equation (1):
E = Basal + (Emax-Basal) * (τ [A])^n / ((τ [A])^n+(Ka + [A])^n),           (1)
where [A] denotes the concentration of hCG and E is the quantification of its effect (cAMP and 
steroid production).  The basal  parameter  is  the baseline  of the response,  Emax is  the maximal 
possible response of the system, τ is  the efficacy,  Ka is  the functional  equilibrium dissociation 
constant of the agonist and n is the Hill slope of the transducer function that links occupancy to 
response. As detailed in Van der Westhuizen et al. , such an equation (1) is badly parametrized to 
yield proper identification of the transduction coefficient, so we transformed the equation (1) using 
standard algebraic manipulations, into equation (2):
E = Basal + (Emax-Basal) / (1 + ((1+[A]/10^(log (Ka))/(10^Log (R) * [A]))^n,           (2)
Also, for a given response Basal, Emax, and n were imposed to have the same value for all input  
(response specific parameters) and n was set to 1 to improve parameter identifiability. Finally, τ and 
Ka  were  taken  as  treatment  specific.  Then,  log  (R_DMSO),  log  (R_ADX68692),  log 
(R_ADX68693),  log  (Ka_ADX68692),  and  log  (Ka_ADX68693)  were  determined  by statistical 
fitting together with Basal, Emax and n. Data-fitting of such a model were performed using the 
D2D-software, on Matlab 14, and parameter uncertainty was quantified using the profile likelihood 
method  and standard hessian calculations. For DMSO input (in the absence of NAMs), the log (Ka) 
was  fixed  to  0.  For  all  dose-response  curves,  except  testosterone  response  in  the  presence  of 
ADX68693 treatment, the transduction coefficient log (R) = log (τ/ Ka) was found to be practically 
identifiable, with finite narrow confidence interval (of total length from half a log to one log). Mean 
transduction coefficient together with the standard error on the mean was then estimated. Still for a 
single dose-response curve, the relative effectiveness between two treatments t1 and t2 (for instance, 
DMSO vs NAMs) is given by:
Δlog (τ/ Ka) = log (τ/ Ka)_t1 – log (τ/ Ka)_t2
To obtain bias factor comparison for two different responses (1 and 2), treatment biases is then given 
by:
 ΔΔlog (τ/ Ka) = Δlog (τ/ Ka)_respone 1 – Δlog (τ/ Ka)_response 2
and the bias factor is the exponential of the latter,
BF= 10^ΔΔlog (τ/ Ka) 
Finally, standard deviation on ligand biases is determined by the standard deviation of the relative 
effectiveness, the latter being determined by the data-fitting procedure. After standard calculation, 
mean bias factor together with their standard error were evaluated from the data. Finally, two-way 
unpaired t-test was performed to obtain the significance of the bias factors.
3. Results 
In this  study we investigated the effects of two compounds,  ADX68692 and ADX68693 
previously shown acting as NAMs on FSHR in vitro and in vivo , on LH/CGR. For this, we used 
three different cell types, HEK293 transiently co-expressing LH/CGR with the different sensors for 
cAMP and ß-arrestin 2 measurements using bioluminescence resonance energy transfer (BRET) 
approach  and  murine  Leydig  tumor  cell  line  (mLTC-1)  as  well  as  primary  rat  Leydig  cells 
endougenously expressing LHR for the effects on cAMP production and steroidogenesis.
3.1. Effects of ADX compounds on LH/CGR-mediated cAMP production 
First,  we  confirmed  the  antagonistic  effect  of  ADX68692  and  ADX68693  on  FSHR-
promoted cAMP production in transfected HEK293 cells . Using the Glosensor™ cAMP assay, we 
clearly demonstrated a dose-dependent inhibition of FSH-induced cAMP production in HEK293 
cells stably expressing FSHR, with an IC50 values around µM (Log IC50 values of -5.71  0.21 and 
-5.12  0.23 for ADX68692 and ADX68693, respectively)(Fig. 1A). Next, we examined the effect 
of  the  two  compounds  on  LH/CGR-mediated  cAMP  production  in  HEK293  cells  transiently 
expressing LH/CGR. Accordingly, BRET-based sensor assay previously reported  was conducted 
with different doses of NAMs combined with increasing doses of hCG as indicated. As shown in 
Fig. 1B and C, the dose-dependent response of hCG on its receptor is consistent with a previous 
study using similar assay . Similarly to FSHR, both ADX68692 (Fig. 1B) and ADX68693 (Fig. 1C) 
inhibited LH/CGR-mediated cAMP production in dose-dependent manner, with a significant shift in 
hCG potency (Table 1). However, such an inhibition was not observed at high concentrations of 
hCG (i.e. 10 and 100 nM). When both compounds were compared at sub-saturating concentration of 
the hormone (0.1 nM), ADX68693 appeared significantly more potent than ADX68692 at 1 µM and 
10 µM (p-value < 0.05) on LH/CGR (Fig. 1D) with pIC50 values of 4.85  0.36 and 5.85  0.14 for 
ADX68692 and ADX68693, respectively. Finally, in order to demonstrate the specificity of both 
compounds on gonadotropin receptors, we tested another Gs-coupled receptor, the vasopressin 2 
receptor (V2R). As shown in Fig. 1E, neither ADX68692 nor ADX68693 (10 µM) affected V2R-
mediated cAMP production assessed with similar BRET-based sensor assay upon its activation with 
DDAVP. Together, our results confirm the previous data showing ADX68692 and ADX68693 as 
FSHR NAMs in rat granulosa primary cells  and clearly demonstrate that these compounds also 
inhibit Gs/cAMP pathway mediated by LH/CGR in HEK293 cells. 
Next, real-time kinetics of cAMP production were performed using 20 minutes pretreatment 
with 10 µM of NAMs followed by rapid activation with 1 nM of hCG. As shown in Fig. 2A, hCG 
nicely  induced  cAMP  production  in  time-dependent  manner  and  both  NAMs  blocked  such 
responses  to  different  extent.  Interestingly,  when  comparing  both  NAMs,  ADX68693  appeared 
significantly stronger than ADX68692 on LH/CGR-mediated response, which is consistent with the 
difference in the inhibitory effect at 1 nM of hCG shown in  Fig. 1B (for ADX68692) and C (for 
ADX68693).  In  order  to  examine  whether  the  NAMs could  reverse  the  gonadotropin-mediated 
response, we performed real-time kinetics where cells were first stimulated with hCG and either 
NAM (10 µM) being applied 5 minutes later.  This resulted in rapid time-dependent decrease in 
hCG-promoted cAMP production (Fig. 2B), demonstrating the antagonistic action of the two NAMs 
even when the receptor is fully activated by hCG such as in the physiological situation.
To  link  our  data  on  Gs/cAMP pathway  with  an  integrated  cellular  response,  a  cAMP-
responsive  element  (CRE)-driven luciferase  reporter  assay  was implemented.  This  assay  uses  a 
pSOM-Luc  plasmid  coding  for  the  firefly  luciferase  under  the  control  of  the  CRE  of  the 
somatostatin 5’ regulatory region, as previously reported . The gonadotropin-promoted luciferase 
expression was assessed in HEK293 cells  transiently co-expressing either FSHR used here as a 
positive control (Fig. 3A) or LH/CGR (Fig. 3B) stimulated with increasing concentrations of FSH 
or hCG, respectively. The treatment of cells with 10 µM of ADX68692 or ADX68693 significantly 
diminished the maximal responses (Emax) with a slight effect on the potency of FSH (Fig. 3A) and 
hCG (Fig. 3B) on their respective receptors (Table 1). These data indicated a negative allosteric 
effect of the compounds on FSHR as well as LH/CGR. Together with the cAMP data, these data 
demonstrate  the  antagonism  of  both  NAMs  on  the  cAMP/PKA/CREB  signaling  pathways  of 
LH/CGR. Moreover, the comparison between the two NAMs on LH/CGR showed ADX68693 being 
stronger than ADX68692 (p-value < 0.001 at 100 nM of hCG), which is consistent with the kinetic 
data shown in Fig. 2. 
3.2. Effects of ADX compounds on β-arrestin 2 recruitment to LH/CGR 
Next,  the effect of ADX68692 and ADX68693 on the recruitment  of β-arrestin  2 to the 
activated LH/CGR in real-time and in live cells was investigated using BRET technology. For this, 
cells co-expressing LH/CGR-Rluc8 (BRET donors) and yPET-ß-arrestin 2 (BRET acceptor) were 
used as previously reported . As shown in Fig. 4, the dose-dependent response of hCG is consistent 
with the previous study using similar assay . Consistent with gene reporter data shown in  Fig. 3, 
increasing doses of both ADX68692 (Fig. 4A) and ADX68693 (Fig. 4B) strongly reduced hCG-
promoted ß-arrestin 2 recruitment, with maximal effect observed at 10 µM of NAMs indicating a 
negative  allosteric  effect  (Table  1).  The  comparison  between  the  two  NAMs  at  the  maximal 
response of the hormone observed at 100 nM showed that ADX68693 is significantly more potent 
than ADX68692 (p-value < 0.01 at 0.5 µM and 1 µM of NAMs,) on LH/CGR (Fig. 4C) with pIC50 
values of 6.02  0.11 and 6.824  0.11 for ADX68692 and ADX68693, respectively. Again, we used 
the recruitment of ß-arrestin 2 to V2R as a negative control, showing that neither ADX68692 nor 
ADX68693  affected  DDAVP-promoted  V2R-ß-arrestin  2  association  (Fig.  4D)  and  further 
demonstrating the specificity of these compounds on gonadotropin receptors.
In addition, real-time kinetics was performed using 10 µM of NAMs and 100 nM of hCG. 
After 20 minutes of pre-treatment with either ADX68692 or ADX68693, a total inhibition of hCG-
promoted ß-arrestin 2 recruitment was observed with both NAMs (Fig. 4E). Such an inhibition is 
consistent  with  that  observed  in  dose-response  analysis  (Fig.  4A and  B).  In  order  to  examine 
whether hCG-mediated ß-arrestin 2 response could be reversed with the NAMs, we performed real-
time kinetics where cells were first stimulated with hCG to promote ß-arrestin 2 recruitment and 12 
minutes later either NAM (10 µM) was applied. Interestingly, the addition of NAMs inhibited ß-
arrestin 2 recruitment very rapidly, indicating that the action of the two compounds occurred even 
when  the  receptor  is  fully  activated  by  hCG  (Fig.  4F)  such  as  in  the  physiological  situation. 
Together these data demonstrate the profound inhibition of ß-arrestin recruitment to LH/CGR by 
ADX68692 and ADX68693. 
3.3. Effect of ADX compounds on LHR-mediated steroidogenesis in mLTC-1 and primary rat 
Leydig cells 
In order  to  link the foregoing data  on LH/CGR in transfected  HEK293 cells  to a  more 
integrated physiological response, a murine Leydig tumor cell line (mLTC-1) as well as primary rat 
Leydig cells, known to endogenously express LHR and to trigger hCG responses were used . Thus, 
the antagonistic effects of the two NAMs at 10 µM were examined on cAMP, progesterone, and 
testosterone  production  in  both  mLTC-1  and  primary  rat  Leydig  cells.  In  cAMP  assay,  both 
ADX68692 and ADX68693 nicely inhibited hCG-promoted cAMP production in mLTC-1 (Fig. 5A) 
and primary rat Leydig cells (Fig. 5B) cells. This was observed even at high concentrations of hCG, 
which is consistent with the NAM action of the two compounds observed in the gene reporter assay 
in  HEK293  cells  (Fig.  3),  demonstrating  an  effect  on  hCG Emax  as  illustrated  in  (Table  2). 
Furthermore, these data are consistent with cAMP data obtained in HEK293 cells since ADX68693 
led to a significantly stronger inhibition of cAMP production than ADX68692 (p-value < 0.01 for 
100 nM of hCG) with a slight shift in the potency of hCG (Table 2). 
Next,  we  examined  the  effects  of  ADX68692  and  ADX68693  on  progesterone  and 
testosterone production induced by hCG stimulation in mLTC-1 and primary rat Leydig cells using 
HTRF®-based  assays.  For  progesterone  in  mLTC-1  cells,  neither  ADX68692  nor  ADX68693 
affected hCG-induced progesterone production (Fig. 5C) as illustrated in  Table 2. By contrast, in 
primary rat Leydig cells  while ADX68692 surprisingly appeared to potentiate (by  37%) hCG-
promoted progesterone, ADX68693 dramatically (by  70%) inhibited such a response (Fig. 5D)
(Table 3). However, in testosterone assay the data obtained in mLTC-1 (Fig. 5E) and primary rat 
Leydig (Fig. 5F) cells are very consistent since ADX68692 only partially inhibited hCG-promoted 
response whereas ADX68693 had a full antagonistic effect (p-value < 0.001 when ADX68692 and 
ADX68693 were compared with each other from 0.1 to 100 nM of hCG). Indeed, the strength of the 
two NAMs on the maximal testosterone response of hCG in both cell models were to similar levels 
with 30-40% and 90% of inhibition by ADX68692 and ADX68693, respectively (Table 2 and 3). 
Together, these observations suggest that the two NAMs present biased effects on the LHR 
in  mLTC-1 and primary  rat  Leydig  cells.  In  addition,  the  bias  calculation  revealed  that,  when 
compared to DMSO, both ADX68692 (Fig. 6A) and ADX68693 (Fig. 6B)  lead to significant bias 
toward progesterone production compated to cAMP response, in mLTC-1 cells: i.e. both NAMs are 
significantly more potent to inhibit cAMP response than progesterone production in mLTC-1 cells 
(Table  4).  In  addition,  to  a  certain  extent  ADX68692  also  shows  a  bias  toward  testosterone 
compared to cAMP response (Table 4). For both NAMs, the inhibition of steroid production in 
mLTC-1  cells  showed  in  Fig.  5C  and E nicely  showed  biased  effects  towards  progesterone 
compared to  testosterone as illustrated in  Fig. 6C, even though the lack of identifiability of the 
testosterone  response  (the  transduction  coefficient  is  poorly  identifiable),  due  to  almost  full 
inhibition by ADX68693, prevents to obtain a significant statistical result (Table 4). By contrast, in 
primary rat Leydig while ADX68692, when compared to DMSO, showed significant bias toward 
progesterone  production  compared  to  both  cAMP  response  and  testosterone  production, 
ADX68693, in turn, when compared to DMSO, showed an opposite bias, toward cAMP compared 
to progesterone production: ADX68693 has a stronger inhibitory effects of the hCG response on 
progesterone production than cAMP (Table 5).
Finally,  the  comparison  beween  the  two  NAMs  indicated  that  the  inhibitory  effects  of 
ADX68693 are moderately biased with respect to cAMP and testosterone responses compared to 
progesterone production, both in mLTC-1  cells (Fig. 6C and Table 4) and primary rat Leydig cells 
(Fig 7C and Table 5).
4. Discussion 
Two compounds, ADX68692 and ADX68693, have been recently reported to act as NAMs at 
the FSHR, leading to the inhibition of FSH-promoted steroidogenesis in rat granulosa primary cells 
and follicle maturation in vivo . Interestingly, despite their structural similarities, the two molecules 
presented different antagonistic profiles at the FSHR. While ADX68692 blocked FSHR-promoted 
cAMP production and progesterone as well as estradiol production, ADX68693 inhibited cAMP and 
progesterone with the same efficacy as ADX68692 but did not block estradiol production . Thus, 
because  of  structural  and  signaling  similarities  between  FSHR and  LH/CGR,  as  well  as  their 
implication  in  the  physiology  of  reproduction,  the  effects  of  ADX68692  and  ADX68693  were 
studied on LH/CGR. We investigated the effects on the two major transduction mechanisms known 
to operate at the LH/CGR: Gs/cAMP/PKA and ß-arrestins. Those studies were extended to examine 
the compounds’ effects on the control of steroidogenesis using mLTC-1 cell line and primary rat 
Leydig  cells  endogenously  expressing  LHR.  Together,  our  data  clearly  demonstrate  that  both 
ADX68692 and ADX68693 inhibited LH/CGR activation by hCG in HEK293 and mLTC-1 as well 
as primary rat Leydig cells. Indeed, both cAMP production and ß-arrestin recruitment induced by 
hCG  were  inhibited  in  a  dose-dependent  manner.  In  addition,  differential  inhibition  of  hCG-
promoted steroid production by ADX68692 and ADX68693 was observed when mLTC-1 cell line 
and primary rat Leydig cells were compared. These constitute the first small molecules antagonizing 
LH/CGR since only agonist compounds were reported so far for this receptor . This finding is of 
great importance regarding the potential application of ADX68692 and ADX68693 to control the 
reproductive activity, considering the involvement of both FSHR and LH/CGR in this function and 
their co-expression within granulosa cells at specific stages of the female reproductive cycle. In fact, 
the physiological effects of FSH and LH on the ovary are characterized by the stimulation of the 
production of estradiol and progesterone, which play key roles in ovarian function and control of the 
reproductive  cycle  .  The  mechanisms  involved  in  the  regulation  of  progesterone  production  by 
ovarian  granulosa  cells  imply  the  activation  of  the  Gs/cAMP/PKA  pathway  leading  to  the 
modulation  of  gene  expression  associated  with  steroidogenesis  such  as  the  steroidogenic  acute 
regulatory protein (StAR), 3ß-hydroxysteroid dehydrogenase (3ßHSD), and the cytochrome P450 
(P450scc) enzyme system . Other studies also reported a crosstalk between ERK activation and 
progesterone production downstream of PKA, with ERK exerting a negative feedback on steroid 
production . For LH/CGR, other molecular mechanisms, including its transactivation with EGFR 
were proposed to play role in steroidogenesis and thereby oocyte maturation, and in gonadotropin-
stimulated  follicles  .  Taken  together  with  the  previous  data  on  the  FSHR  ,  our  study  using 
ADX68692 and ADX68693 highlights the complexity of the mechanisms involved in the control of 
steroidogenesis via FSHR and LH/CGR.
In  cAMP  assay,  the  allosteric  antagonism  of  both  NAMs  was  also  shown  to  reverse 
gonadotropin-induced cAMP production  in  real-time kinetic  assay  (Fig.  2).  The relatively  slow 
kinetics of such inhibition is likely due to strong accumulation of cAMP before the addition of 
NAMs since the assay is based on intracellular cAMP using BRET sensor. Moreover, kinetic and 
dose-response analysis indicated that ADX68693 is more efficient than ADX68692 to inhibit hCG-
promoted cAMP production in HEK293 cells, whereas the opposite situation seems to happen on 
FSHR in HEK293 cells with ADX68692 being more effeicient than ADX68693 (data not shown for 
the kinetics). These obseravtions suggest different allosteric properties of the two NAMs towards 
FSHR and LH/CGR, which may be explained by the differences in the specific domains involved in 
the  binding  of  NAMs  on  each  receptor.  Moreover,  these  different  profiles  may  explain  the 
differential effects of the two NAMs on steroidogenesis whether FSHR  or LHR is targeted (see 
below).  From  the  structure  point  of  view,  the  only  major  difference  between  ADX68692  and 
ADX68693 is the presence of pyridine group in ADX68692 . This may determine the allosteric 
properties of the NAMs and thereby explain the differences between FSHR and LH/CGR. The fact 
that there was no significant difference in NAMs’ efficacies on LH/CGR-mediated cAMP response 
in HEK293 cells  is  likely due to the high level  of receptor  expression achieved in this  system. 
Indeed, we recently reported that in a similar experimental setting, maximal cAMP response could 
be reached with less than 5% of receptor occupied , meaning that a substantial amount of spare 
receptors  are  available  thereby  preventing  the  NAMs to  reduce  maximum efficacies  and rather 
leading to shifts in EC50 values of hCG . Whereas in mLTC-1 and primary rat Leydig cells, both 
NAMs  profoundly  decreased  the  maximal  hCG-induced  cAMP  production  with  ADX68693 
appearing more efficient than ADX68692 (Table 2 and  3). Again, this likely reflects the fact that 
mLTC-1  and  primary  rat  Leydig  cells  express  less  receptors,  hence  less  spare  receptors,  than 
transfected HEK293 cells. These data were also consistent with the reporter gene assay indicating 
downstream inhibition of the cAMP/PKA/CREB-dependent pathway.
In addition to Gs/cAMP pathway, ß-arrestins are known to play a major role not only in the 
desensitization of GPCRs but also in their ability to signal independently of G proteins . Indeed, 
many studies demonstrated the interaction of ß-arrestins with gonadotropin receptors and, in some 
cases, their involvement in receptor signaling . Moreover, the role of ß-arrestins in steroidogenic 
pathways has been demonstrated for aldosterone production mediated by the angiotensin II receptor 
(AT1R) . In the present study, we report that, at maximal dose (10 µM), the two NAMs completely 
abolished ß-arrestin 2 recruitment to LH/CGR. Real-time kinetics showed that both NAMs very 
rapidly reversed hCG-promoted ß-arrestin 2 recruitment in HEK293 cells. The fact that, in the same 
cellular system (i.e. transfected HEK293 cells), the NAMs led to a shift in EC50 for cAMP response 
whereas  they  had  profound  effects  on  hCG  maximal  response  when  measuring  ß-arrestin  2 
recruitment  is  consistent  with  our  previous  finding that  100% receptor  occupancy  needs  to  be 
reached in order to achieve maximal ß-arrestin recruitment . This is nicely illustrated by the shift (3 
logs) in hCG dose-response when ß-arrestin 2 response was compared to cAMP response.
Interestingly,  when we attempted to link our data on cAMP and ß-arrestins  observed in 
HEK293 cells to hCG-promoted steroid production in mLTC-1 and primary rat Leydig cells, our 
data were reminiscent of the previous study on FSHR . In addition, our data in mLTC-1 taken along 
with those obtained in primary rat  Leydig cells  showed the complexity of the pathways linking 
cAMP pathway and progesterone production. In fact, Dias et al. showed that ADX68692 blocked 
FSHR-promoted  cAMP  production  and  progesterone  as  well  as  estradiol  production,  while 
ADX68693 acted with the same efficacy as ADX68692 on cAMP and progesterone inhibition but 
interestingly  did not  block  estradiol  production  .  However,  here we clearly  showed that  neither 
ADX6892 nor ADX68693 had significant effects on progesterone production in mLTC-1 cells even 
though both nicely decreased hCG-induced cAMP production. In contrast, in primary rat Leydig 
cells  ADX68693  but  not  ADX68692  nicely  inhbited  hCG-promoted  progesterone  production. 
Wethere these differences between mLTC-1 and primary rat Leydig cells  are due to the species 
(mice  versus rat)  or  cells  (cell  line  versus primary  cells)  is  still  unclear.  This  also true for  the 
unexpected potentiating effects of ADX68692 observed in primary rat Leydig cells compared to 
mLTC-1 cells. 
For testosterone responses, the situation is more concordant between mLTC-1 and primary 
rat Leydig cells since ADX6892 led to partial inhibition whereas ADX68693 completely abolished 
hCG-promoted  testosterone  production.  In  addition,  these  data  confirm  the  better  efficacy  of 
ADX68693 compared to ADX68692 on LH/CGR. This reveals interesting biased effects of both 
NAMs on LH/CGR: both NAMs blocked the canonical Gs/cAMP pathway and ADX68692 only 
partially  inhibited  hCG-induced  testosterone  but  ADX68693  completely  inhibited  hCG-induced 
testosterone production in both mLTC-1 and primary rat Leydig cells. However, neither compounds 
significantly  affected  progesterone  response  in  mLTC-1  cells  but  in  primary  rat  Leydig  cells 
ADX68693 dramatically inhibited progesterone while ADX68692 would have a positive effect. Such 
biased effects were nicely supported by our bias quantification using the original operational model 
and recently applied for other GPCRs (Fig. 6). The original work on FSHR in rat granulosa primary 
cells  clearly supports the link between cAMP pathway and progesterone production, indicating that 
alternative and/or additional pathways are involved in estradiol production. In line with this, our data 
suggest that progesterone and testosterone production induced by LHR in mLTC-1 cells may not 
entirely depend on the cAMP pathway. Thus, progesterone and testosterone production seems to be 
controlled by distinct signaling pathways yet to be identified.
The total inhibition by both NAMs of ß-arrestin 2 recruitment to LH/CGR in HEK293 cells 
suggests that this transduction mechanism may play an important role in testosterone production. 
Together,  these observations  further  illustrate the complexity of the mechanisms involved in the 
control of steroidogenesis  via FSHR and LH/CGR. Such a discrepancy between cAMP/ß-arrestin 
inhibition and steroid production is in fact difficult to reconcile with the classical view postulating 
that  progesterone  production  depends  on  the  activation  of  the  Gs/PKA/cAMP  pathway.  One 
possibility  is  the  engagement  of  Gs-  and  ß-arrestin-independent  transduction  mechanisms. 
Candidates include other G proteins (Gq/Gi) known to couple to both FSHR and LH/CGR (for 
review ) and could be differentially inhibited by the NAMs. Alternatively, the absence of significant 
inhibition of progesterone in mLTC-1 cells may be due to the residual cAMP response even upon 
treatment with NAMs. Moreover, our data cannot rule out the possibility of differential inhibition of 
intermediate pathways downstream of cAMP or ß-arrestins controlling steroid production. This may 
be consistent with a scenario where the activation of both Gs/cAMP and ß-arrestin pathways would 
be involved to a different extent (e.g. with different activation thresholds) in the production of both 
progesterone  and  testosterone  production.  Differences  in  the  kinetics  of  progesterone  and 
testosterone production may also account for the observed biased effects between the two NAMs .
Finally, this study demonstrates that ADX68692 and ADX68693 antagonized LH/CGR with 
differential profiles regarding their canonical Gs/cAMP and ß-arrestin pathways. Even though their 
cross-reactivity  on LH/CGR has yet  to be demonstrated  in vivo,  our findings suggest that these 
compounds may impact the steroidogenic pathways differently as a function of FSHR and LH/CGR 
relative expression levels. Exploring this possibility will require further investigations in vitro and in  
vivo. It will be important to take into account the fact that the two receptors are co-expressed in the 
same follicular cells at specific stages of the female reproductive cycle. Interestingly, recent studies 
in transfected cells reported heterodimerization between FSHR and LH/CGR with the physiological 
relevance  still  to  be  demonstrated  .  Nevertheless,  the  intriguing  possibility  exists  that  the 
pharmacological  profiles  of  the  two  NAMs  on  FSHR-LH/CGR heterodimer  could  be  different 
compared to the respective protomers or homodimers. Furthermore, the differences in the biased 
effects  of  ADX68692  and  ADX68693  with  respect  to  steroid  production  that  was  previously 
observed on FSHR  and that our study revealed on LH/CGR as well, suggest that the combination of 
both NAMs may be required for efficient contraceptive or therapeutic applications to achieve full 
inhibition of steroidogenesis.
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Table 1: Efficacy (Emax) and efficiency (pEC50) of hCG on LH/CGR measured in different 
assays in HEK293 cells treated or not with 10 µM of NAMs. 
Treatments / 
responses
hCG + DMSO
Emax (%)                    pEC50  
hCG + ADX68692
   Emax (%)                   pEC50  
hCG + ADX68693
 Emax (%)                pEC50    
cAMP   100                     10.67  0.05 92.01  2.97             9.66  0.09 105  2.27           8.93  0.06 
pSOM-Luc   100                       9.35  0.09 55.89  4.40             8.78  0.19 31.57  2.30        8.88  0.17 
ß-arrestin 2   100                       8.12  0.08 10.65  1.62                   ND  4.99  2.15                ND  
Table 2: Efficacy (Emax) and efficiency (pEC50) of hCG on LHR measured in different assays 
in mLTC-1 cells treated or not with 10 µM of NAMs. 
Treatments / 
responses
hCG + DMSO
Emax (%)                    pEC50  
hCG + ADX68692
   Emax (%)                   pEC50  
hCG + ADX68693
 Emax (%)                pEC50    
cAMP   100                     10.10  0.09 42.67  2.53             9.16  0.18 23.80  2.71        9.14  0.34 
Progesterone   100                     11.28  0.14 99.84  10.14         11.13  0.39 95.29  8.22      11.32  0.35 
Testosterone   100                     11.34  0.18 67.73  4.22           10.77  0.21 7.94  2.23                ND  
Table 3: Efficacy (Emax) and efficiency (pEC50) of hCG on LHR measured in different assays 
in primary rat Leydig cells treated or not with 10 µM of NAMs. 
Treatments / 
responses
hCG + DMSO
Emax (%)                    pEC50  
hCG + ADX68692
   Emax (%)                   pEC50  
hCG + ADX68693
 Emax (%)                pEC50    
cAMP   100                     10.01  0.06 63.85  3.05             9.52  0.14 33.66  3.01        9.56  0.28 
Progesterone   100                     12.19  0.22 136.80  3.78         11.77  0.12 30.38  6.34      10.70  1.05 
Testosterone   100                     11.59  0.33 61.89  4.11           11.44  0.25 11.93  5.11                ND  
Table 4: Bias factor of the effects of both NAMs on hCG-promoted responses in mLTC-1 cells 
calculated as described Material and Methods. 
Treatments / responses ADX68692  /  DMSO
Bias factor         p-value
ADX68693  /  DMSO
Bias factor          p-value
ADX68693  /  ADX68692
Bias factor              p-value
Progesterone/cAMP
Testosterone/cAMP
Progesterone/testosterone
8.24                        0.012
2.49                        0.123
3.31                        0.024
19.27                      0.033
0.94                        0.979
20.46                      0.186
2.34                           0.381
0.38                           0.652
6.18                           0.404
Table 5: Bias factor of the effects of both NAMs on hCG-promoted responses in primary rat 
Leydig cells calculated as described Material and Methods. 
Treatments / responses ADX68692  /  DMSO
Bias factor         p-value
ADX68693  /  DMSO
Bias factor          p-value
ADX68693  /  ADX68692
Bias factor              p-value
Progesterone/cAMP
Testosterone/cAMP
Progesterone/testosterone
5.88                      0.0002
0.47                      0.32
12.55                    0.03
0.24                         0.09
13.61                       0.74
0.02                         0.62
0.04                           0.004
29.06                         0.67
0.001                         0.44
Figure Legends 
Fig. 1: Dose-response analysis of the effects of ADX compounds on cAMP production . HEK293 
cells stably expressing FSHR (A) or transiently co-expressing LH/CGR (B, C, and D) or V2R (E) 
with cAMP pGloSensor™-22F (A) or the cAMP-BRET sensor (B,  C,  D, and E), were used for 
dose-response analysis of hormone-promoted cAMP production. For this, cells were first pretreated 
or not for 20 minutes at 37°C with the different concentrations of ADX68692 or ADX68693 as 
indicated. Then, cells were stimulated or not for 30 minutes at 37°C with increasing concentrations 
of FSH (A), hCG (B and  C) or DDAVP (E) before luminescence and BRET measurements. The 
curves  in  panel  D  were generated  by pretreating  cells  with increasing concentrations  of NAMs 
followed  by  stimulation  with  0.1  nM  of  hCG.  Data  are  means  ±  SEM  of  three  experiments 
performed in duplicate. 
Fig. 2: Real-time kinetics of the effects of ADX compounds on cAMP production.  HEK293 
cells transiently co-expressing LH/CGR and the cAMP-BRET sensor were used for kinetic analysis 
of  hCG-promoted cAMP production.  For  this,  cells  were  first  pretreated  (A)  or  not  (B)  for  20 
minutes at 37°C with either DMSO or 10 µM of ADX68692 or ADX68693 as indicated. Then,  
BRET measurements were rapidly performed upon addition of 1 nM of hCG followed (B) or not 
(A)  by NAMs addition as indicated.  Data  are representative  of  three  experiments  performed in 
triplicate. 
Fig. 3: Effects of ADX compounds on cAMP sensitive reporter gene expression. HEK293 cells 
transiently co-expressing the cAMP sensitive reporter gene (pSOM-Luc) and either the FSHR (A) 
or LH/CGR (B) were first starved overnight and pretreated or not for 1 hour at 37°C with 10 µM of 
ADX68692 or ADX68693. Then cells were stimulated or not for 6 hours at 37°C with increasing 
concentrations of FSH (A) or hCG (B) before luciferase luminescence was measured using Bright-
Glo™ luciferase assay. Data are means ± SEM of four independent experiments performed in single 
point. 
Fig. 4: Effects of ADX compounds on ß-arrestin 2 recruitment. HEK293 cells transiently co-
expressing yPET-ß-arrestin 2 and either LH/CGR-Rluc8 (A, B, C, E and F) or V2R-Rluc8 (D), were 
used for dose-response and real-time kinetic analysis of hormone-promoted BRET increases. For 
dose-responses,  cells  were  first  pretreated  or  not  for  20  minutes  at  37°C  with  the  different 
concentrations of ADX68692 or ADX68693 as indicated. Then, cells were stimulated or not for 30 
minutes at 37°C with the increasing concentrations of hCG or DDAVP before BRET measurements 
were  performed.  The  curves  in  panel  C  were  generated  by  pretreating  cells  with  increasing 
concentrations of NAMs followed by stimulation with 100 nM of hCG. For the kinetics, cells were 
first pretreated (A) or not (B) for 20 minutes at 37°C with either DMSO or 10 µM of ADX68692 or 
ADX68693 as indicated. Then, BRET measurements were rapidly performed upon addition of 100 
nM of hCG followed (B) or not (A) by NAMs addition as indicated. Data are means ± SEM of 
three-six experiments performed in duplicate. 
Fig. 5: Effects of ADX compounds on LHR activation in mLTC-1 and primary rat Leydig 
cells. mLTC-1 (A, C, and E) and primary rat Leydig (B, D, and F) cells endogenously expressing 
the LHR were used for cAMP, progesterone and testosterone production as indicated. For cAMP, 
cells  were first  pretreated  for  20 minutes  at  37°C with  either  DMSO 10 µM of  ADX68692 or 
ADX68693, and then stimulated or not for 30 minutes at 37°C with the increasing concentrations of 
hCG before cAMP production was assessed by HTRF®-based assay, as described in Material and 
Methods. For steroid production, cells were first pretreated for 1 hour at 37°C with either DMSO or 
10 µM of ADX68692 or ADX68693 as indicated. Then, cells were stimulated or not for 3 hours (for 
primary rat Leydig cells) or 24 hours (for mLTC-1 cells) at 37°C with increasing concentrations of 
hCG before progesterone (C  and D) and testosterone (E  and F) production was quantified using 
HTRF®-based  assay.  Data  are  means  ±  SEM  of  three  independent  experiments  performed  in 
duplicate (for mLTC-1 cells) or six independent experiments performed in single point (for Leydig 
cells).
Fig. 6: Bias plots of NAMs effects in mLTC-1 cells.  The biased effects of both NAMs on hCG-
promoted  responses  in  mLTC-1 cells  were  calculated  as  described  Material  and Methods.  The 
analysis of hCG-induced cAMP, progesterone, and testosterone was performed at different doses of 
hCG and this for the different treatments, DMSO versus ADX68692 (A), DMSO versus ADX68693 
(B), and ADX68692 versus ADX68693 (C) as indicated. 
